1. Home
  2. Analysis
  3. Ranolazine
  4. Embolex

Ranolazine and Embolex drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported only by a few people who take Ranolazine and Embolex together.

The phase IV clinical study analyzes what interactions people who take Ranolazine and Embolex have. It is created by eHealthMe based on reports of 2 people who take the same drugs from the FDA, and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Jan, 30, 2023

2 people who take Ranolazine and Embolex together, and have interactions are studied.

What is Ranolazine?

Ranolazine has active ingredients of ranolazine. eHealthMe is studying from 9,053 Ranolazine users for its effectiveness, alternative drugs and more.

What is Embolex?

Embolex has active ingredients of dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride. eHealthMe is studying from 1,148 Embolex users for its effectiveness, alternative drugs and more.

Number of Ranolazine and Embolex reports submitted per year:

Ranolazine and Embolex drug interactions.

Common Ranolazine and Embolex drug interactions by gender *:

female:

  1. Agranulocytosis
  2. Weight decreased
  3. Anaemia
  4. Aplastic anaemia
  5. Dyspnoea
  6. Exercise tolerance decreased
  7. Haematoma
  8. Pneumonia
  9. Pyrexia
  10. Thrombocytopenia

male:

  1. Malignant melanoma stage i

Common Ranolazine and Embolex drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

  1. Agranulocytosis
  2. Anaemia
  3. Aplastic anaemia
  4. Dyspnoea
  5. Exercise tolerance decreased
  6. Haematoma
  7. Pneumonia
  8. Pyrexia
  9. Thrombocytopenia
  10. Weight decreased

* Approximation only. Some reports may have incomplete information.

Do you take Ranolazine and Embolex?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Browse all drug interactions of Ranolazine and Embolex:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Ranolazine side effects:

Browse all side effects of Ranolazine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Embolex side effects:

Browse all side effects of Embolex:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Ranolazine interactions:

Browse all interactions between Ranolazine and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Embolex interactions:

Browse all interactions between Embolex and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on ranolazine and dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride (the active ingredients of Ranolazine and Embolex, respectively), and Ranolazine and Embolex (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Ranolazine and Embolex.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2023 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.